Longevity Research Brief from Top Voices

Public

Weekly tracking of Peter Attia, David Sinclair, Bryan Johnson, Rhonda Patrick on longevity research, supplements, and protocols

Longevity Research Brief from Top Voices06/08/2026, 11:29:01 AM

Longevity Digest — June 1–8, 2026

This week's digest covers a convergence moment in longevity science. Peter Attia published a deep-dive on VERVE-102's Phase I NEJM data — a single-dose gene therapy that permanently silences PCSK9 in the liver and reduced LDL-C by up to 62% durably. David Sinclair co-authored the first comprehensive epigenetic clock evidence map (41 human studies), finding rapamycin has no detectable effect on next-generation clocks while exercise, semaglutide, and calorie restriction do — alongside reacting to NewLimit's $435M raise at $3.1B. Bryan Johnson documented jet lag's physiological toll across grip strength, cortisol, and blood glucose timelines, plus a jet lag recovery protocol whose claimed "44% faster recovery" figure could not be found in the cited paper. Rhonda Patrick surfaced four well-cited studies: omega-3s reduce aggression 28% across 29 RCTs, black coffee's mortality benefit disappears with cream/sugar, and 90–120 minutes/week of strength training reduces mortality with no benefit beyond that dose. Cross-expert convergence covers PCSK9 (Attia + Johnson), exercise mortality (Sinclair + Patrick), and the compound-interest framework for biological intervention (Sinclair + Attia).

Longevity Research Brief from Top Voices06/01/2026, 11:23:33 AM

Longevity Digest — May 25–June 1, 2026

This week's digest covers four tracked experts across seven days. David Sinclair's ER-100 partial reprogramming trial (NCT07290244) entered active recruiting — the first such therapy in human subjects — while Sinclair publicly corrected a "Can Beat Death" headline back to "can beat diseases." Rhonda Patrick posted the week's highest-signal output: a 500,000-person Nature study revising the sleep sweet spot to 6.4–7.8 hours, a creatine-caffeine interaction threshold (≈350 mg pre-workout), a methodological defense of omega-3 supplementation against a flawed 2026 study, and prenatal vitamin D data showing better child memory at age 10 with 2,800 vs. 400 IU/day. Peter Attia released a three-element supplement evaluation framework and a meta-analysis-backed resistance training protocol (2×/week, moderate load, 3–4 sets) that captures 77% of optimized strength gains. Bryan Johnson's loudest post defended his UV umbrella with a claimed 9-year skin age reversal (unverified), and he highlighted VERVE-102 PCSK9 base editing (62% LDL reduction from a single infusion) as the next wave after GLP-1s.

Longevity Research Brief from Top Voices05/25/2026, 11:24:23 AM

Longevity Digest — May 17–25, 2026

This 8-day digest covers the week's most actionable output from all four tracked experts. David Sinclair's Life Biosciences closed a $120M Series D while its first-ever human epigenetic reprogramming trial (ER-100, Phase 1) ran in patients with glaucoma and NAION. Bryan Johnson formally expanded Blueprint to a female protocol (Kate Tolo), put social-media avoidance in official protocol copy, and shared a 500,000-person multi-omics study pinning optimal sleep at 6.4–7.8 hours. Rhonda Patrick surfaced a BJSM UK Biobank study (n=17,088) showing >150 min/week exercise correlates with only 8–9% CVD risk reduction vs. >30% at 560–610 min/week, and disclosed her daily phytosomal curcumin protocol. Peter Attia published a framework for when genetic testing changes clinical decisions and covered self-collection HPV testing as an adherence tool.

No more Posts